Institutional Review Board, Hospital for Special Surgery
March 17, 2010
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
Douglas E. Padgett, MD
Michael M. Alexiades, MD
Friedrich Boettner, MD
Robert L. Buly, MD
Struan H. Coleman, MD, PhD
Alejandro Gonzalez Della Valle, MD
David L. Helfet, MD
Dean G. Lorich, MD
David J. Mayman, MD
Michael J. Maynard, MD
Peter J. Moley, MD
Danyal H. Nawabi, MD
Bryan J. Nestor, MD
Amar S. Ranawat, MD
Anil S. Ranawat, MD
Edwin P. Su, MD
Roger F. Widmann, MD
This is an observational study including all patients who present to the Center for Hip Preservation with a primary diagnosis of hip pain. The enrollment period and duration of follow-up is indefinite.
• Patients who present to the Center for Hip Preservation
• Primary diagnosis of hip pain
• Patients who do not consent to take part in the registry
• Patients diagnosed with advanced osteoarthritis
• Patients who have undergone total hip arthroplasty or resurfacing
• Patients who are indicated for total hip arthroplasty or resurfacing